Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory subjects, 18-70 years of age, inclusive~* For female subjects, the following conditions must be met Postmenopausal status for at least 1 year, or Status post surgical sterilization, or If of childbearing potential, utilization of adequate birth control and willingness to undergo urine beta-hcg testing prior to drug treatment and on every study day~Exclusion Criteria:~* Secondary causes of hypertension~* Diabetes type 1 or type 2 as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication~* Use of hormone replacement therapy~* Statin or fibrate therapy~* A seated systolic blood pressure(SBP) greater than 179 mmHg or a seated diastolic blood pressure(DBP) greater than 110 mmHg~* Pregnancy~* Breast-feeding~* Cardiovascular disease such as history of myocardial infarction, presence of angina pectoris, significant arrhythmia, congestive heart failure, (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy~* Treatment with anticoagulants~* History of serious neurologic diseases such as cerebral hemorrhage,stroke, or transient ischemic attack~* History or presence of immunological or hematological disorders~* Diagnosis of asthma~* Clinically significant gastrointestinal impairment that could interfere with drug absorption~* Impaired hepatic function (aspartate aminotransferase \[AST\] and or alanine aminotransferase \[ALT\] \> 2.0 x upper range)~* Known preexisting gallbladder disease~* Impaired renal function (eGFR \< 60 ml/min/1.73M2)~* Hematocrit \< 35%~* Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult~* Treatment with a glucocorticoid therapy~* Treatment with lithium salts~* History of of alcohol or drug abuse~* Treatment with any investigational drug in the 1 month preceding the study~* Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study~* Inability to comply with the protocol, e.g uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Placebo, then fenofibrate (Type: PLACEBO_COMPARATOR): Randomized study of fenofibrate versus placebo during high salt diet
- Fenofibrate, then placebo (Type: PLACEBO_COMPARATOR): Randomized study of fenofibrate versus placebo during high salt intake.

Based on this trial design, predict the completion outcome and termination type (if applicable).